Organization
Biocity Biopharmaceutics Co., Ltd., Shanghai, China
1 abstract
Abstract
An open-label, multicenter, phase Ib/II study of the ATR inhibitor SC0245 in combination with irinotecan in patients with relapsed and refractory extensive stage small cell lung cancer (ES-SCLC).Org: Department of Medical Oncology, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China, Department of Thoracic Oncology, Tianjin Key Laboratory of Cancer Prevention and Therapy, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin’s Clinical Research Center for Cancer, Tianjin, China, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China, Biocity Biopharmaceutics Co., Ltd., Shanghai, China, Department of Medical Oncology, Shanghai Chest Hospital, Shanghai, China,